Drug Profile
Research programme: haemostasis therapy - Haemostatix
Alternative Names: HaemoPlax; HXTC-901; Systemic haemostat - HaemostatixLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Haemostatix
- Class Albumins; Peptides
- Mechanism of Action Fibrin stimulants; Fibrinogen modulators; Platelet aggregation stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Surgical blood loss; Thrombocytopenia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Thrombocytopenia in United Kingdom (IV, Infusion)
- 04 Nov 2017 No recent reports of development identified for research development in Surgical-blood-loss(Prevention) in United Kingdom (IV, Infusion)
- 06 Aug 2014 Early research in prevention of Surgical blood loss is ongoing in United Kingdom (IV)